Target Name: CD96
NCBI ID: G10225
Review Report on CD96 Target / Biomarker Content of Review Report on CD96 Target / Biomarker
CD96
Other Name(s): CD96 molecule, transcript variant 1 | TACT_HUMAN | T-cell surface protein tactile | t cell-activated increased late expression protein | CD96 variant 1 | CD96 molecule | Cell surface antigen CD96 | T cell-activated increased late expression protein | T cell activation, increased late expression | TACTILE | T-cell surface protein tactile (isoform 1) | cell surface antigen CD96

CD96 Molecule: A Potential Drug Target and Biomarker

CD96 is a protein that is expressed in various tissues and cells of the human body. It is a member of the immunoglobulin superfamily and has been implicated in various biological processes. CD96 has also been identified as a potential drug target and biomarker. In this article, we will explore the CD96 molecule, its potential drug targeting, and its role as a biomarker for various diseases.

CD96 Molecule: Structure and Function

CD96 is a type-I transmembrane protein that consists of 158 amino acids. It has a molecular weight of 17.1 kDa and a calculated pI of 1.67. CD96 is expressed in various tissues, including the brain, spleen, thymus, lung, liver, and pancreas. It is also expressed in peripheral blood mononuclear cells (PBMCs) and T-cells.

CD96 is involved in various signaling pathways, including cell adhesion, migration, and survival. It has been shown to play a role in the regulation of immune responses, inflammation, and fibrosis. CD96 has also been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

CD96 as a Drug Target

CD96 has been identified as a potential drug target due to its various functions in disease. One of the main reasons for its potential as a drug target is its involvement in immune regulation. CD96 has been shown to regulate the maturation and function of natural killer cells, which are important for immune surveillance against tumors.

Another potential mechanism for CD96's drug targeting is its role in cancer progression. Studies have shown that CD96 is expressed in various types of cancer and that it is involved in the development and progression of these diseases. Also, it has been shown to be a negative regulator of the T-cell receptor ?± chain, which is a key receptor for T-cell activation and proliferation.

CD96 has also been shown to be involved in the regulation of inflammation. It has been shown to play a role in the regulation of inflammatory responses and has been implicated in the development of various inflammatory diseases.

CD96 as a Biomarker

CD96 has also been identified as a potential biomarker for various diseases. One of the main reasons for its potential as a biomarker is its involvement in disease signaling pathways. As a drug target, CD96 has been shown to regulate various signaling pathways, including those involved in cancer, neurodegenerative diseases, and autoimmune diseases. This means that changes in CD96 levels or activity may provide information about the presence or progression of these diseases.

Another potential mechanism for CD96's use as a biomarker is its role in the regulation of immune responses. As previously mentioned, CD96 has been shown to regulate the maturation and function of natural killer cells, which are important for immune surveillance against tumors. Therefore, changes in CD96 levels or activity may provide information about the immune response to a particular tumor.

Conclusion

CD96 is a protein that has various functions in the body, including immune regulation and cancer progression. Its potential as a drug target and biomarker makes it an attractive target for research and development of new treatments for various diseases. Further studies are needed to fully understand the role of CD96 in disease and its potential as a drug and biomarker.

Protein Name: CD96 Molecule

Functions: May be involved in adhesive interactions of activated T and NK cells during the late phase of the immune response. Promotes NK cell-target adhesion by interacting with PVR present on target cells. May function at a time after T and NK cells have penetrated the endothelium using integrins and selectins, when they are actively engaging diseased cells and moving within areas of inflammation

The "CD96 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD96 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19